GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cloudbreak Pharma 2592.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2022FY2025

Net income

−$67.7m

FY2022FY2025

Free cash flow

−$69.7m

FY2022FY2025

Shareholders' equity

$60.5m

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue—$10.0m——
Research and development$66.8m$37.9m$27.5m$15.3m
Operating income−$107.4m−$37.2m−$35.8m−$23.7m
Net income−$67.7m−$99.1m−$129.4m−$66.8m
Diluted earnings per share-0.08-0.12-0.15-0.08

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets$66.6m$40.0m$64.8m$82.1m
Total liabilities$6.1m$391.6m$327.6m$227.3m
Shareholders' equity$60.5m−$351.5m−$262.8m−$145.2m
Shares outstanding845m839m845m845m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−$51.5m−$26.5m−$22.5m−$20.1m
Capital spending−$18.2m−$155,000−$2.2m−$778,000
Free cash flow−$69.7m−$26.7m−$24.7m−$20.8m

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024
Revenue—$10.0m—
Operating income−$33.0m−$37.2m−$27.3m
Net income$5.2m−$99.1m−$52.1m
Diluted earnings per share0.01-0.12-0.06
Cash from operations−$19.0m——
Total assets$25.7m$40.0m—
Shareholders' equity−$330.2m−$351.5m—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income65.4%——
Net income0.4%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-8.1

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.